Where to buy 25I-NBOMe for sale online

The emergence of research chemicals in the online marketplace has raised significant concerns about their availability, safety, and regulation. 25I-NBOMe, often marketed as a designer drug, is one such substance that has garnered attention for its potential risks and accessibility. When it comes to purchasing 25I-NBOMe, the role of online sellers and vendors cannot be ignored.

Research chemical sellers play a pivotal role in the distribution of substances like 25I-NBOMe. These sellers often promote their products as “for sale” through various online platforms, making it easily accessible to the general public. The allure of purchasing such substances online lies in the anonymity and convenience it offers to buyers.

However, this ease of access comes with significant drawbacks. One of the primary concerns is the lack of regulation and oversight in the sale of research chemicals. Many online vendors operate in a legal gray area by labeling these substances as “not for human consumption.” This labeling allows them to evade certain regulations that apply to pharmaceuticals or controlled substances. Consequently, buyers may unknowingly expose themselves to serious health risks when they buy and consume these substances.

The limited research on 25I-NBOMe’s safety profile makes it even more crucial for responsible and ethical practices among sellers. Without proper testing and quality control, buyers are left in the dark about the purity and potency of the substance they purchase.

Moreover, the marketing of 25I-NBOMe as a designer drug raises ethical questions about the intentions behind its production and sale. Many online vendors exploit legal loopholes to profit from substances that can have severe health consequences when misused.

Summary

25I-NBOMe, also recognized as 2C-I-NBOMe, NBOMe-2C-I, Cimbi-5, Smiles, and among the substances colloquially termed N-Bomb, belongs to the novel category of psychedelic compounds within the phenethylamine chemical class. This distinctive substance elicits a broad spectrum of predominantly visual and stimulating psychedelic effects upon administration.
The nomenclature 25I-NBOMe, derived as a shorthand reference to 2C-I-NBOMe, originates from the phenethylamine-based psychedelic compound 2C-I. The compound’s synthesis and initial documentation date back to 2003, attributed to Ralf Heim of the Free University of Berlin. Subsequent research endeavors were spearheaded by a team led by David Nichols at Purdue University. Notably, 25I-NBOMe has been examined in its 11C radiolabeled form as a potential ligand for mapping the distribution of 5-HT2A receptors in the brain, employing positron emission tomography (PET).
It merits attention that substances from the NBOMe family, especially 25I-NBOMe and 25N-NBOMe, should be administered sublingually by placing them in the oral cavity and allowing gradual absorption over 15-25 minutes.
Regrettably, comprehensive knowledge concerning the pharmacological attributes, metabolic processes, and toxicity of 25I-NBOMe in humans remains limited. This compound had no history of human usage until it emerged for sale online as a designer drug in 2010. Notably, it has been associated with numerous fatalities and hospitalizations. Anecdotal accounts indicate that the use of this substance may pose challenges in ensuring safety, primarily due to its heightened sensitivity to dosage and unpredictable effects.

Identifiers
show IUPAC name
CAS Number	919797-19-6 hydrochloride: 1043868-97-8
PubChem CID	10251906
ChemSpider	8427392
UNII	547KGL06IPhydrochloride: 0V30416N51
ChEMBL	ChEMBL1908863
CompTox Dashboard (EPA)	DTXSID20238808
Chemical and physical data
Formula	C18H22INO3
Molar mass	427.282 g·mol−1

Chemistry

25I-NBOMe, also recognized as 2C-I-NBOMe, belongs to the serotonergic class and is a derivative of the substituted phenethylamine psychedelic compound 2C-I. Structurally, 25I-NBOMe is a substituted phenethylamine featuring methoxy groups (CH3O-) attached to carbons R2 and R5, accompanied by an iodine atom affixed to carbon R4. Its distinction from 2C-I lies in a substitution on the amine (NH2) group, which is replaced by a 2-methoxybenzyl (BOMe) group. This NBOMe addition substitution encompasses a methoxy ether (CH3O-) bonding to a benzene ring at R2.

Pharmacology

25I-NBOMe exhibits notable efficacy at the 5-HT2A receptor, acting as a full agonist in this context. Nevertheless, the precise nature of these interactions and how they contribute to the psychedelic experience remains shrouded in mystery.
Within the realm of psychedelics, this compound stands out for its remarkable pharmacological characteristics, marked by its exceptionally high potency, affinity, and selectivity when binding to the 5-HT2A receptor. It is worth noting that while it is not classified as a “full agonist,” questions persist regarding how its effects diverge from those induced by other 5-HT2A partial agonists, a category encompassing traditional psychedelics.
Notably, the Ki values for a range of targets exceed 500 Ki, including 5-HT1A, D3, H2, 5-HT1D, α1A adrenergic, δ opioid, serotonin reuptake transporter, 5-HT5A, 5-HT1B, D2, 5-HT7, D1, 5-HT3, 5-HT1E, D5, muscarinic M1-M5, H3, and the dopamine reuptake transporter.

Receptor	Ki (nM)	±
5-HT2A	0.044
5-HT2C	2
5-HT6	73	12
μ-opioid	82	14
H1	189	35
5-HT2B	231	73
κ-opioid	288	50

Subjective effects

Disclaimer: The ensuing effects listed below reference the Subjective Effect Index (SEI), which relies on open research literature derived from anecdotal user reports and analyses by contributors to PsychonautWiki. Consequently, they should be approached with a critical perspective.

Additionally, it’s essential to acknowledge that these effects may not necessarily manifest predictably or reliably, although higher doses are more inclined to elicit the complete spectrum of effects. Furthermore, it’s vital to be aware that escalating doses heighten the likelihood of adverse effects, including addiction, severe harm, or even fatality ☠.

Physical:

• Stimulation: 25I-NBOMe is commonly associated with pronounced physical energy and stimulation. It typically induces a unique kind of physical vigor characterized by heightened energy levels, yet it doesn’t compel the user to move unless they consciously choose to do so. Some users, however, may experience uncontrollable stimulation, leading to bodily tremors and teeth grinding reminiscent of MDMA and traditional stimulants like amphetamines.
• Perception of Bodily Lightness: Users often feel extraordinarily light, sometimes to the extent of feeling weightless.
• Spontaneous Physical Sensations: The “body high” entails a mild, pervasive, euphoric tingling sensation. This tingling is accompanied by spontaneous waves of euphoria, which become more prolonged and pronounced with escalating dosage.
• Mouth Numbing: Immediately following sublingual absorption, users typically experience a potent, unpleasant metallic taste and a distinct numbness in the mouth and tongue that can persist for up to an hour after ingesting the blotter paper.
• Nausea: During the initial stages of the experience, nausea may arise and lead to initial vomiting. However, nausea often subsides as the trip unfolds, making it relatively mild compared to psychedelics like psilocin, 2C-E, and 2C-I.
• Temperature Regulation Suppression
• Increased Bodily Temperature
• Abnormal Heartbeat
• Increased Heart Rate
• Increased Blood Pressure
• Muscle Contractions
• Muscle Cramps
• Muscle Tension
• Gustatory Hallucination
• Vasoconstriction
• Appetite Suppression
• Stomach Cramps
• Dehydration
• Dry Mouth
• Difficulty Urinating or Frequent Urination
• Restless Legs
• Pupil Dilation
• Headaches
• Seizures

Visual:

• Enhancements
  • Visual Acuity Enhancement
  • Color Enhancement
  • Pattern Recognition Enhancement
  • Magnification: At higher doses, users may experience a “fish-eye” effect, with magnification varying based on the user’s gaze relative to objects.
• Suppressions
  • Frame Rate Suppression
  • Peripheral Information Misinterpretation
• Distortions
  • Drifting (Melting, Flowing, Breathing, and Morphing): This effect is characterized by detailed, slow, and smooth motion, appearing static and cartoon-like.
  • Colour Shifting
  • Color Replacement
  • Color Tinting
  • Depth Perception Distortions
  • Perspective Distortions
  • Tracers
  • Diffraction
  • Brightness Alteration
  • After Images
  • Symmetrical Texture Repetition
  • Recursion
  • Scenery Slicing

Geometry:

The visual geometry induced by 25I-NBOMe resembles that of LSD, characterized as algorithmic, intricate, finely detailed, fast-moving, structured, colorful, glossy, sharp, and possessing angular and rounded corners. It surpasses the intricacy of visual geometry seen in 2C-I and most of the 2C-x family, closely resembling LSD, Psilocin, and DMT at sufficiently high doses. 25I-NBOMe’s geometry intensifies when users fixate on a central point, enveloping their visual field and creating the impression of entering a constantly shifting, vast, geometric landscape.

Hallucinatory States:

25I-NBOMe consistently generates hallucinatory states ranging from level 1 to 3. Level 4 hallucinatory breakthroughs, though reported, differ significantly from those produced by more common psychedelics like psilocin, 2C-E, and DMT. These hallucinatory effects encompass:

• Transformations
• Machinescapes: An uncommon effect that manifests at very high doses, often accompanied by overwhelming and potentially hazardous physical and cognitive effects.
• Internal Hallucination: In dim environments, internal hallucinations are lucid, interactive, and predominantly themed around personal, spiritual, science-fiction, fantasy, surreal, nonsensical, or metaphysical concepts.

Cognitive:

The cognitive effects of 25I-NBOMe are often regarded as relatively mild compared to classical psychedelics. At low to moderate doses, individuals might feel that their thought stream remains generally normal in its particular style. However, high doses can lead to pronounced cognitive alterations, including confusion, amnesia, and sensory overload. Prominent cognitive effects encompass:

• Analysis Enhancement: Typically evident at low doses.
• Thought Acceleration and Deceleration: Although the substance can accelerate thought, the opposite may occur at higher doses.
• Conceptual Thinking: Mild in comparison to traditional psychedelics.
• Anxiety & Paranoia: Occurs more readily than with other psychedelics, likely due to its prominent stimulating properties.
• Feelings of Impending Doom: Typically experienced during the comedown or after consuming large amounts.
• Empathy, Affection, and Sociability Enhancement: Entactogenic effects range from mild to potent but manifest inconsistently. Increased sociability, love, and empathy are less intense than those induced by other entactogens like MDMA, 2C-B, and AMT.
• Memory Suppression
• Ego Death
• Amnesia
• Novelty Enhancement
• Immersion Enhancement
• Emotion Enhancement
• Increased Sense of Humor
• Laughter Fits
• Increased Music Appreciation
• Personal Bias Suppression
• Increased Libido
• Time Distortion
• Wakefulness
• Hallucinogen Persisting Perception Disorder (HPPD)

Auditory:

• Enhancements
• Distortions
• Hallucinations

Multi-sensory:

• Dosage Independent Intensity: This substance may produce unexpectedly solid or weak effects even at seemingly identical doses, contributing to its relative risk compared to most other psychedelics.
• Synaesthesia: A rare and non-reproducible effect that becomes more likely with increased dosage, primarily experienced by those predisposed to synaesthetic states.

Transpersonal: The transpersonal effects of 25I-NBOMe appear less consistent and reproducible than those of other psychedelics, reflecting its notably mild alterations to perceptual and cognitive processes.

• Existential Self-Realization
• Unity and Interconnectedness

Toxicity

The usage of NBOMes, both in the short term and long term, has occasionally been associated with severe physical and mental issues affecting seemingly random individuals. These problems encompass memory and speech difficulties, heart complications, Hallucinogen Persisting Perception Disorder (HPPD), and, in certain instances, anxiety and post-traumatic stress disorder (PTSD) stemming from particularly challenging experiences.

25I-NBOMe, a relatively recent substance, remains poorly understood regarding its pharmacological risks and interactions with other compounds. The LD50 (lethal dose for 50% of subjects) has yet to be determined, although it can potentially be fatal at high doses. It is strongly advised against insufflating 25I-NBOMe, as this method has been linked to several deaths in recent years.

This substance came under media scrutiny in early 2012 following a cluster of seven non-fatal overdoses in or near Richmond, Virginia. As of May 2013, 25I-NBOMe has reportedly been associated with five overdose deaths in the United States. In June 2012, two teenagers in Grand Forks, North Dakota, and East Grand Forks, Minnesota, fatally overdosed on what was purportedly 25I-NBOMe, resulting in lengthy sentences for two individuals and a federal indictment against an online vendor based in Texas.

In October 2012, a 21-year-old man from Little Rock, Arkansas, died after nasally ingesting a liquid drug drop at a music festival. It is unclear what other substances he may have consumed, as autopsies typically do not test for the presence of research chemicals.

In Australia, a man died from injuries sustained by colliding with trees and power poles while under the influence of 25I-NBOMe. Additionally, a 16-year-old in Brazil reportedly died from an overdose in April 2016.

Including 5-HTP can significantly amplify the effects of 25I-NBOME and should be avoided. It is highly recommended to employ harm reduction practices when using this substance.

Tolerance and Addiction Potential:

25I-NBOMe is not associated with addiction, and the desire to use it may diminish with use. Typically, users self-regulate their consumption.

Tolerance to the effects of 25I-NBOMe develops almost immediately upon ingestion. Tolerance takes approximately one week to decrease by half and two weeks to return to baseline without further use. 25I-NBOMe leads to cross-tolerance with all psychedelics, meaning that consuming 25I-NBOMe reduces the effects of other psychedelics.

Overdose:

Due to its high potency and seemingly unpredictable effects, the margin between a typical dose and an overdose of NBOMe compounds is exceedingly narrow compared to many other substances. The precise toxic dose remains unclear, as it depends considerably on individual physiology rather than solely on the dosage. Nevertheless, anecdotal reports suggest dangerous side effects can emerge when doses exceed 1000 μg, potentially becoming lethal for more sensitive individuals at around 2000 μg. Some people survive much higher doses, sometimes without significant side effects.

Additionally, there is uncertainty surrounding the dosage on blotter paper, as laying out an exact dosage can be challenging. Insufflating, vaporizing, or consuming tinctures of this substance is strongly discouraged due to this uncertainty and its association with documented fatalities. One study discovered that 25I‐NBOMe and 25C‐NBOMe blotter papers contained ‘hotspots’ with higher drug concentrations, posing a risk of overdose.

Overdose effects of NBOMes typically include a dangerously elevated heart rate, blood pressure, hyperthermia, and pronounced vasoconstriction. These physical symptoms are often accompanied by confusion, delusions, panic attacks, aggressive behavior, numbness or pain, amnesia, and sometimes seizures. Overdose risks range from organ failure to cardiac arrest and potential fatality. There are multiple reports of individuals fatally injuring themselves or succumbing to falls.

Benzodiazepines or antipsychotics may help manage the psychological effects during an overdose, although immediate medical attention should be sought even in cases of suspected 25I-NBOMe overdose.

Dangerous Interactions:

Interactions between 25I-NBOMe and other substances can be unpredictable and potentially hazardous. Due to the unpredictable nature of the NBOMe series, it is generally recommended to avoid combining them with other psychoactive substances. Some of the known dangerous interactions include:

• 2C-T-X: The 2C-T-X phenethylamines and NBOMes are known for their unpredictable interactions, making avoiding this combination.
• 5-MeO-xxT: The 5-MeO tryptamines can also have unpredictable interactions with NBOMes, further emphasizing avoiding this combination.
• Amphetamines: Combining amphetamines with NBOMes can result in tachycardia, hypertension, vasoconstriction, and, in severe cases, heart failure. The anxiety-inducing effects of stimulants can also lead to unpleasant thought loops, which can be exacerbated when combined with psychedelics.
• aMT
• Caffeine: Caffeine can intensify the natural stimulation of psychedelic drugs, potentially leading to discomfort. High doses of caffeine can cause anxiety, which can be challenging to manage while under the influence of psychedelics.
• Cannabis: Cannabis has an unexpectedly strong and unpredictable synergy with the effects of psychedelics. Caution is advised when combining the two, as it can significantly increase the risk of adverse psychological reactions such as anxiety, paranoia, panic attacks, and psychosis. Users should start with a fraction of their usual cannabis dose and take extended breaks between consumption to avoid excessive intake.
• Cocaine: Cocaine and NBOMes both provide significant stimulation, which, when combined, can result in severe vasoconstriction, tachycardia, hypertension, and, in extreme cases, heart failure.
• DOx
• DXM
• Lithium: Lithium, often prescribed for bipolar disorder, is linked to an increased risk of psychosis and seizures when combined with psychedelics. This combination is strongly discouraged.
• MAOIs: MAO-B inhibitors can unpredictably increase the potency and duration of phenethylamines.
• MDMA
• MXE: MXE, as an NMDA antagonist, can potentiate NBOMes, leading to intensely unpleasant experiences.
• Tramadol: Tramadol is known to lower the seizure threshold, and NBOMes tend to cause severe seizures.

Legal status

As of September 2014, the European Council resolved that 25I-NBOMe would be subjected to control measures and criminal penalties by Member States by October 2, 2015.

Here is the legal status of 25I-NBOMe in various countries:

• Australia: Possession, production, and sale are illegal.
• Austria: Since June 26, 2019, 25I-NBOMe has been illegal to possess, produce, and sell under the SMG (Suchtmittelgesetz Österreich).
• Brazil: Possession, production, and sale are illegal as it is listed on Portaria SVS/MS nº 344.
• Canada: 25I-NBOMe is considered Schedule III as it is a derivative of 2,5-dimethoxyphenethylamine.
• China: As of October 2015, 25I-NBOMe is a controlled substance in China.
• Denmark: 25I-NBOMe is controlled by the generic classification of phenethylamines in the Executive Order on Euphoriant Substances.
• Germany: 25I-NBOMe is controlled under Anlage I BtMG (Narcotics Act, Schedule I)[26] as of December 13, 2014. Manufacturing, possessing, importing, exporting, buying, selling, procuring, or dispensing it without a license is illegal.
• Finland: 25I-NBOMe is controlled under the Medicines Act (395/87) as of March 15, 2013.
• Hungary: 25I-NBOMe falls within the generic definition of phenethylamines in Schedule C of Government Decree 66/2012.[25]
• Israel: The drug was banned in 2012.
• Italy: In Italy, 25I-NBOMe is a Schedule 1 controlled substance, meaning it’s illegal in this state.
• Japan: 25I-NBOMe is a narcotic drug in Japan, effective November 1, 2015.
• Latvia: 25I-NBOMe is a Schedule I controlled substance.[32]
• New Zealand: 25I-NBOMe is a Schedule 2 controlled substance in New Zealand.
• Norway: 25I-NBOMe is controlled by the generic scheduling of phenethylamines as of February 14, 2013.
• Poland: 25I-NBOMe falls under the definition of a ‘substitution drug’ under the Act on Counteracting Drug Addiction and the Act on State Sanitary Inspection, 2010. Its marketing and production are penalized with a fine (administrative sanctions).
• Romania: In 2011, Romania banned all psychoactive substances, regardless of composition.
• Russia: Possession, production, and sale are illegal.
• Slovenia: 25I-NBOMe was included in a Decree amending the classification of illicit drugs (Official Gazette of RS No. 62/2013).
• Sweden: 25I-NBOMe is classified as Schedule I.
• Switzerland: 25I-NBOMe is a controlled substance named explicitly under Verzeichnis D.
• United Kingdom: 25I-NBOMe is a Class A drug in the United Kingdom due to the N-benzyl phenethylamine catch-all clause.
• United States: On November 15, 2013, the DEA added 25I-NBOMe to Schedule I using their emergency scheduling powers, making it “temporarily” in Schedule I for 2 years.

FAQ

1. What is 25I-NBOMe?

25I-NBOMe, also known as 2C-I-NBOMe or simply “N-Bomb,” is a synthetic psychedelic substance belonging to the phenethylamine chemical class. It is known for its potent hallucinogenic effects when administered.

2. How is 25I-NBOMe typically administered?

25I-NBOMe is often taken sublingually by placing it under the tongue and allowing it to absorb over 15-25 minutes. This method is standard due to its potency and rapid onset.

3. What are the effects of 25I-NBOMe?

25I-NBOMe produces various effects, including visual distortions, stimulation, altered perception of reality, and hallucinations. It can also induce feelings of euphoria and heightened sensory perception.

4. Is 25I-NBOMe safe to use?

25I-NBOMe has numerous health risks, including severe physical and mental side effects. It has been linked to overdose, hospitalization, and even death. Using 25I-NBOMe is considered unsafe and should be avoided.

5. Is 25I-NBOMe addictive?

25I-NBOMe is not considered habit-forming, and its use does not typically lead to addiction. The desire to use it may decrease with repeated use.

6. What are the potential dangers of using 25I-NBOMe?

The dangers of using 25I-NBOMe include severe health risks such as heart problems, seizures, hallucinogen persisting perception disorder (HPPD), anxiety, and even post-traumatic stress disorder (PTSD) from difficult experiences.

7. Is 25I-NBOMe legal?

The legal status of 25I-NBOMe varies by country. In many places, possessing, producing, or selling is illegal due to its potential risks and abuse.

8. How long does the effect of 25I-NBOMe last?

The effects of 25I-NBOMe can last for several hours, typically around 6 to 10 hours. However, the duration may vary depending on the dosage and individual factors.

9. Can 25I-NBOMe be used safely with other substances?

Combining 25I-NBOMe with other substances can be extremely dangerous and is strongly discouraged. It may lead to unpredictable interactions and increase the risk of adverse effects.

References

1. Erowid 25I-NBOMe (2C-I-NBOMe) Vault: Fatalities / Deaths
2. Erowid NBOMe (Other or Unknown NBOMe-Compound) Vault: Fatalities / Deaths
3. Heim, R. (2004). “Synthese und Pharmakologie potenter 5-HT2A-Rezeptoragonisten mit N-2 -Methoxybenzyl-Partialstruktur: Entwicklung eines neuen Struktur-Wirkungskonzepts”. doi:10.17169/refubium-16193. Retrieved 10 May 2013.
4. Braden, M. R. (January 1, 2007). “Towards a biophysical understanding of hallucinogen action.” Theses and Dissertations Available from ProQuest: 1–176. Retrieved August 8, 2012.
5. Ettrup, A., Hansen, M., Santini, M. A., Paine, J., Gillings, N., Palner, M., Lehel, S., Herth, M. M., Madsen, J., Kristensen, J., Begtrup, M., Knudsen, G. M. (April 2011). “Radiosynthesis and in vivo evaluation of a series of substituted 11C-phenethylamines as 5-HT (2A) agonist PET tracers”. European Journal of Nuclear Medicine and Molecular Imaging. 38 (4): 681–693. doi:10.1007/s00259-010-1686-8. ISSN 1619-7089.
6. Hansen, M. (2010). Design and synthesis of selective serotonin receptor agonists for positron emission tomography brain imaging: PhD thesis. Faculty of Pharmaceutical Sciences, University of Copenhagen. ISBN 9788792719003.
7. Nichols, D. E., Frescas, S. P., Chemel, B. R., Rehder, K. S., Zhong, D., Lewin, A. H. (June 1, 2008). “High specific activity tritium-labeled N-(2-methoxybenzyl)-2,5-dimethoxy-4-iodophenethylamine (INBMeO): a high-affinity 5-HT2A receptor-selective agonist radioligand”. Bioorganic & Medicinal Chemistry. 16 (11): 6116–6123. doi:10.1016/j.bmc.2008.04.050. ISSN 1464-3391.
8. Geller, L. (2012), Kids overdosing on a new drug, WWBT NBC12
9. New street drugs are causing concern among medics. Vanessa Araiza, WBRC, February 28, 2012, | http://www.wsfa.com/story/16977573/new-street-drug-causing-concern-among-medics
10. “New drug N-bomb hits the street, terrifying parents, troubling cops | url=https://www.nydailynews.com/news/national/new-synthetic-hallucinogen-n-bomb-killing-users-cops-article-1.1336327
11. Breaking Bad: Digital Drug Sales, Analog Drug Deaths. Craig Malisow, Houston Press, March 13, 2013 | http://www.houstonpress.com/2013-03-14/news/motion-research-charles-carlton/
12. Martin, N. (2012), 21-year-old dies after one drop of new synthetic drug at Voodoo Fest, NOLA.
13. New hallucinogenic drug 25B-NBOMe and 25I-NBOMe led to South Australian man’s bizarre death | http://www.adelaidenow.com.au/news/south-australia/new-hallucinogenic-drug-25b-nbome-and-25i-nbome-led-to-south-australian-mans-bizarre-death/story-e6frea83-1226472672220/
14. Erowid 2C-C-NBOMe (25C-NBOMe) Vault: Fatalities / Deaths
15. Lützen, E., Holtkamp, M., Stamme, I., Schmid, R., Sperling, M., Pütz, M., Karst, U. (April 2020). “Multimodal imaging of hallucinogens 25C‐ and 25I‐NBOMe on blotter papers”. Drug Testing and Analysis. 12 (4): 465–471. doi:10.1002/dta.2751. ISSN 1942-7603.
16. Marchi, N. C., Scherer, J. N., Fara, L. S., Remy, L., Ornel, R., Reis, M., Zamboni, A., Paim, M., Fiorentino, T. R., Wayhs, C. A. Y., Von Diemen, L., Pechansky, F., Kessler, F. H. P., Limberger, R. P. (March 1, 2019). “Clinical and Toxicological Profile of NBOMes: A Systematic Review.” Psychosomatics. 60 (2): 129–138. doi:10.1016/j.psym.2018.11.002. ISSN 0033-3182.
17. Yoon, K. S., Yun, J., Kim, Y.-H., Shin, J., Kim, S. J., Seo, J.-W., Hyun, S.-A., Suh, S. K., Cha, H. J. (1 April 2019). “2-(2,5-Dimethoxy-4-methylphenyl)-N-(2-methoxybenzyl)ethanamine (25D-NBOMe) and N-(2-methoxybenzyl)-2,5-dimethoxy-4-chlorophenethylamine (25C-NBOMe) induce adverse cardiac effects in vitro and in vivo”. Toxicology Letters. 304: 50–57. doi:10.1016/j.toxlet.2019.01.004. ISSN 0378-4274.
18. https://psychonautwiki.org/wiki/File:Nbome_death_news_i2013e0190_disp.jpg
19. https://psychonautwiki.org/wiki/File:Nbome_death_news_i2013e0191_disp.jpg
20. “Council Implementing Decision on subjecting 25I-NBOMe, AH-7921, MDPV, and methoxetamine to control measures”. Official Journal of the European Union. Office for Official Publications of the European Communities (published October 1, 2014). September 25, 2014. pp. 22–26. OCLC 52224955. L 287.
21. https://www.ris.bka.gv.at/Dokumente/BgblAuth/BGBLA_2019_II_167/BGBLA_2019_II_167.pdfsig
22. http://portal.anvisa.gov.br/documents/10181/3115436/%281%29RDC_130_2016_.pdf
23. Branch, L. S. (2022), Consolidated federal laws of Canada, Controlled Drugs and Substances Act
24. http://www.sfda.gov.cn/WS01/CL0056/130753.html | 关于印发《非药用类麻醉药品和精神药品列管办法》的通知
25. “25I-NBOMe: EMCDDA–Europol Joint Report on a new psychoactive substance: 25I-NBOMe (4-iodo-2,5-dimethoxy-N-(2-methoxybenzyl)phenethylamine)” (PDF). European Monitoring Centre for Drugs and Drug Addiction. 2014. doi:10.2810/27828. ISBN 978-92-9168-682-7. ISSN 1977-7868. Retrieved February 18, 2020.
26. “Anlage I BtMG” (in German). Bundesministerium der Justiz und für Verbraucherschutz. Retrieved December 11, 2019.
27. “Achtundzwanzigste Verordnung zur Änderung betäubungsmittelrechtlicher Vorschriften” (PDF) (in German). Bundesanzeiger Verlag. Retrieved December 11, 2019.
28. “§ 29 BtMG” (in German). Bundesministerium der Justiz und für Verbraucherschutz. Retrieved December 11, 2019.
29. http://www.health.gov.il/LegislationLibrary/25574413.pdf
30. Tabella 1 Stupefacenti dello Stato Italiano |http://www.salute.gov.it/imgs/C_17_pagineAree_3729_listaFile_itemName_0_file.pdf
31. 新たに４物質を麻薬に指定し、規制の強化を図ります ｜報道発表資料｜厚生労働省, 厚生労働省 [Ministry of Health, Labour and Welfare (MHLW)]
32. Zaudējis spēku – Noteikumi par Latvijā kontrolējamajām narkotiskajām vielām, psihotropajām vielām un prekursoriem
33. Misuse of Drugs Act 1975 No 116 (as of December 7 2021), Public Act – New Zealand Legislation
34. Takács, I. G. (2013), Colored City: Recreational drug use in Belgrade
35. http://www.dreptonline.ro/legislatie/legea_194_2011_comba
36. Läkemedelsverkets författningssamling (PDF)
37. “Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien” (in German). Bundeskanzlei [Federal Chancellery of Switzerland]. Retrieved January 1, 2020.
38. The Misuse of Drugs Act 1971 (Ketamine, etc.) (Amendment) Order 2014
39. http://www.justice.gov/dea/divisions/hq/2013/hq111513.shtml